Medications which block enzymes belonging to the kinase family, are among the most effective pharmaceuticals for targeted cancer therapies. Scientists at the German Cancer Consortium (DKTK) at the Technical University of Munich (TUM) have examined 243 kinase inhibitors which are either approved drugs or have been tested in clinical trials. According to results published in Science, some of these may have more applications than previously thought.
Targeted therapy has revolutionized the treatment of certain types of cancer. An important class of drugs are kinase inhibitors, which are particularly successful in treating certain types of blood and lung cancer. ...
